Full Press Release Details
DUBLIN,Sept. 2, 2025/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference inNew York City.
Rick Winningham, CEO, will participate in a Fireside Chat on Tuesday, September 9 at 1:30 PM EDT (10:30 AM PDT / 6:30 PM IST).
Management will be hosting in-person meetings during the event. Interested investors should contact their H.C. Wainwright representative to request a meeting.
A live webcast of the event may be accessedhereor on the "Events and Presentation" page under the Investors section onTheravance.com. A replay of the webcast will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliverMedicines that Make a Difference®in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI®(revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visitwww.theravance.com.THERAVANCE BIOPHARMA®, THERAVANCE®and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI®is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.